nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Flutamide—prostate cancer	0.0688	0.206	CbGbCtD
Duloxetine—CYP2D6—Bicalutamide—prostate cancer	0.0684	0.205	CbGbCtD
Duloxetine—CYP2D6—Abiraterone—prostate cancer	0.0567	0.17	CbGbCtD
Duloxetine—CYP1A2—Estrone—prostate cancer	0.0498	0.149	CbGbCtD
Duloxetine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0326	0.0975	CbGbCtD
Duloxetine—CYP1A2—Estradiol—prostate cancer	0.0286	0.0856	CbGbCtD
Duloxetine—CYP1A2—Etoposide—prostate cancer	0.0187	0.0559	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—prostate cancer	0.0105	0.0314	CbGbCtD
Duloxetine—NPY1R—prostate gland—prostate cancer	0.00499	0.159	CbGeAlD
Duloxetine—NPY1R—seminal vesicle—prostate cancer	0.00422	0.134	CbGeAlD
Duloxetine—CYP1A2—urine—prostate cancer	0.00363	0.115	CbGeAlD
Duloxetine—NPY1R—renal system—prostate cancer	0.0034	0.108	CbGeAlD
Duloxetine—HTR2A—urine—prostate cancer	0.00284	0.0901	CbGeAlD
Duloxetine—CYP2D6—urine—prostate cancer	0.00258	0.0821	CbGeAlD
Duloxetine—NPY1R—testis—prostate cancer	0.0022	0.0698	CbGeAlD
Duloxetine—NPY1R—lymph node—prostate cancer	0.00159	0.0506	CbGeAlD
Duloxetine—SLC6A3—testis—prostate cancer	0.000925	0.0294	CbGeAlD
Duloxetine—CYP1A2—renal system—prostate cancer	0.000887	0.0282	CbGeAlD
Duloxetine—HTR2A—epithelium—prostate cancer	0.000748	0.0238	CbGeAlD
Duloxetine—SLC6A2—testis—prostate cancer	0.000746	0.0237	CbGeAlD
Duloxetine—HTR2A—renal system—prostate cancer	0.000694	0.022	CbGeAlD
Duloxetine—Fluoxetine—CYP3A5—prostate cancer	0.000639	0.176	CrCbGaD
Duloxetine—CYP2D6—renal system—prostate cancer	0.000632	0.0201	CbGeAlD
Duloxetine—SLC6A2—lymph node—prostate cancer	0.000541	0.0172	CbGeAlD
Duloxetine—HTR2A—testis—prostate cancer	0.000448	0.0142	CbGeAlD
Duloxetine—Fluoxetine—CYP2C19—prostate cancer	0.000435	0.12	CrCbGaD
Duloxetine—Cinacalcet—CYP3A4—prostate cancer	0.000433	0.119	CrCbGaD
Duloxetine—CYP2D6—testis—prostate cancer	0.000409	0.013	CbGeAlD
Duloxetine—Propranolol—CYP3A5—prostate cancer	0.00039	0.107	CrCbGaD
Duloxetine—Propranolol—ADRB2—prostate cancer	0.000308	0.0848	CrCbGaD
Duloxetine—Atomoxetine—CYP2C19—prostate cancer	0.000279	0.0768	CrCbGaD
Duloxetine—Fluoxetine—CYP3A4—prostate cancer	0.000276	0.076	CrCbGaD
Duloxetine—Propranolol—CYP2C19—prostate cancer	0.000265	0.073	CrCbGaD
Duloxetine—Propranolol—CYP1A1—prostate cancer	0.000264	0.0727	CrCbGaD
Duloxetine—Atomoxetine—CYP3A4—prostate cancer	0.000178	0.0489	CrCbGaD
Duloxetine—Propranolol—CYP3A4—prostate cancer	0.000169	0.0464	CrCbGaD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.57e-05	0.000149	CcSEcCtD
Duloxetine—Somnolence—Docetaxel—prostate cancer	6.54e-05	0.000148	CcSEcCtD
Duloxetine—Discomfort—Prednisone—prostate cancer	6.54e-05	0.000148	CcSEcCtD
Duloxetine—Eye disorder—Epirubicin—prostate cancer	6.53e-05	0.000148	CcSEcCtD
Duloxetine—Hypersensitivity—Etoposide—prostate cancer	6.52e-05	0.000148	CcSEcCtD
Duloxetine—Tinnitus—Epirubicin—prostate cancer	6.51e-05	0.000148	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—prostate cancer	6.49e-05	0.000147	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.49e-05	0.000147	CcSEcCtD
Duloxetine—Flushing—Epirubicin—prostate cancer	6.48e-05	0.000147	CcSEcCtD
Duloxetine—Cardiac disorder—Epirubicin—prostate cancer	6.48e-05	0.000147	CcSEcCtD
Duloxetine—Dyspepsia—Docetaxel—prostate cancer	6.47e-05	0.000147	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—prostate cancer	6.46e-05	0.000147	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—prostate cancer	6.46e-05	0.000147	CcSEcCtD
Duloxetine—Insomnia—Capecitabine—prostate cancer	6.44e-05	0.000146	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—prostate cancer	6.43e-05	0.000146	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—prostate cancer	6.41e-05	0.000145	CcSEcCtD
Duloxetine—Paraesthesia—Capecitabine—prostate cancer	6.39e-05	0.000145	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—prostate cancer	6.39e-05	0.000145	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—prostate cancer	6.38e-05	0.000145	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—prostate cancer	6.36e-05	0.000144	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—prostate cancer	6.35e-05	0.000144	CcSEcCtD
Duloxetine—Asthenia—Etoposide—prostate cancer	6.35e-05	0.000144	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—prostate cancer	6.35e-05	0.000144	CcSEcCtD
Duloxetine—Anaphylactic shock—Prednisone—prostate cancer	6.34e-05	0.000144	CcSEcCtD
Duloxetine—Oedema—Prednisone—prostate cancer	6.34e-05	0.000144	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—prostate cancer	6.34e-05	0.000144	CcSEcCtD
Duloxetine—Angiopathy—Epirubicin—prostate cancer	6.34e-05	0.000144	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—prostate cancer	6.33e-05	0.000144	CcSEcCtD
Duloxetine—Nausea—Mitoxantrone—prostate cancer	6.32e-05	0.000143	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—prostate cancer	6.31e-05	0.000143	CcSEcCtD
Duloxetine—Infection—Prednisone—prostate cancer	6.3e-05	0.000143	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—prostate cancer	6.29e-05	0.000143	CcSEcCtD
Duloxetine—Pain—Docetaxel—prostate cancer	6.29e-05	0.000143	CcSEcCtD
Duloxetine—Constipation—Docetaxel—prostate cancer	6.29e-05	0.000143	CcSEcCtD
Duloxetine—Dyspepsia—Capecitabine—prostate cancer	6.27e-05	0.000142	CcSEcCtD
Duloxetine—Chills—Epirubicin—prostate cancer	6.27e-05	0.000142	CcSEcCtD
Duloxetine—Pruritus—Etoposide—prostate cancer	6.26e-05	0.000142	CcSEcCtD
Duloxetine—Shock—Prednisone—prostate cancer	6.24e-05	0.000142	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—prostate cancer	6.24e-05	0.000142	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—prostate cancer	6.23e-05	0.000141	CcSEcCtD
Duloxetine—Nervous system disorder—Prednisone—prostate cancer	6.22e-05	0.000141	CcSEcCtD
Duloxetine—Tachycardia—Prednisone—prostate cancer	6.19e-05	0.00014	CcSEcCtD
Duloxetine—Decreased appetite—Capecitabine—prostate cancer	6.19e-05	0.00014	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—prostate cancer	6.17e-05	0.00014	CcSEcCtD
Duloxetine—Skin disorder—Prednisone—prostate cancer	6.16e-05	0.00014	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Capecitabine—prostate cancer	6.15e-05	0.000139	CcSEcCtD
Duloxetine—Fatigue—Capecitabine—prostate cancer	6.14e-05	0.000139	CcSEcCtD
Duloxetine—Hyperhidrosis—Prednisone—prostate cancer	6.13e-05	0.000139	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—prostate cancer	6.12e-05	0.000139	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—prostate cancer	6.11e-05	0.000139	CcSEcCtD
Duloxetine—Constipation—Capecitabine—prostate cancer	6.09e-05	0.000138	CcSEcCtD
Duloxetine—Pain—Capecitabine—prostate cancer	6.09e-05	0.000138	CcSEcCtD
Duloxetine—Erythema—Epirubicin—prostate cancer	6.08e-05	0.000138	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—prostate cancer	6.08e-05	0.000138	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—prostate cancer	6.06e-05	0.000137	CcSEcCtD
Duloxetine—Diarrhoea—Etoposide—prostate cancer	6.06e-05	0.000137	CcSEcCtD
Duloxetine—Anorexia—Prednisone—prostate cancer	6.05e-05	0.000137	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—prostate cancer	6.04e-05	0.000137	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—prostate cancer	6.02e-05	0.000137	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—prostate cancer	6.01e-05	0.000136	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—prostate cancer	6e-05	0.000136	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—prostate cancer	6e-05	0.000136	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—prostate cancer	5.99e-05	0.000136	CcSEcCtD
Duloxetine—Tension—Epirubicin—prostate cancer	5.96e-05	0.000135	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—prostate cancer	5.95e-05	0.000135	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—prostate cancer	5.9e-05	0.000134	CcSEcCtD
Duloxetine—Back pain—Epirubicin—prostate cancer	5.88e-05	0.000133	CcSEcCtD
Duloxetine—Feeling abnormal—Capecitabine—prostate cancer	5.87e-05	0.000133	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—prostate cancer	5.86e-05	0.000133	CcSEcCtD
Duloxetine—Dizziness—Etoposide—prostate cancer	5.85e-05	0.000133	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—prostate cancer	5.84e-05	0.000133	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—prostate cancer	5.84e-05	0.000132	CcSEcCtD
Duloxetine—Gastrointestinal pain—Capecitabine—prostate cancer	5.82e-05	0.000132	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—prostate cancer	5.82e-05	0.000132	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—prostate cancer	5.81e-05	0.000132	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—prostate cancer	5.81e-05	0.000132	CcSEcCtD
Duloxetine—Chills—Doxorubicin—prostate cancer	5.8e-05	0.000132	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Prednisone—prostate cancer	5.78e-05	0.000131	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—prostate cancer	5.77e-05	0.000131	CcSEcCtD
Duloxetine—Insomnia—Prednisone—prostate cancer	5.74e-05	0.00013	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—prostate cancer	5.73e-05	0.00013	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—prostate cancer	5.71e-05	0.00013	CcSEcCtD
Duloxetine—Paraesthesia—Prednisone—prostate cancer	5.7e-05	0.000129	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—prostate cancer	5.66e-05	0.000128	CcSEcCtD
Duloxetine—Urticaria—Capecitabine—prostate cancer	5.66e-05	0.000128	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—prostate cancer	5.64e-05	0.000128	CcSEcCtD
Duloxetine—Body temperature increased—Capecitabine—prostate cancer	5.63e-05	0.000128	CcSEcCtD
Duloxetine—Abdominal pain—Capecitabine—prostate cancer	5.63e-05	0.000128	CcSEcCtD
Duloxetine—Vomiting—Etoposide—prostate cancer	5.63e-05	0.000128	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—prostate cancer	5.62e-05	0.000128	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—prostate cancer	5.62e-05	0.000128	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—prostate cancer	5.62e-05	0.000127	CcSEcCtD
Duloxetine—Agitation—Epirubicin—prostate cancer	5.59e-05	0.000127	CcSEcCtD
Duloxetine—Dyspepsia—Prednisone—prostate cancer	5.58e-05	0.000127	CcSEcCtD
Duloxetine—Rash—Etoposide—prostate cancer	5.58e-05	0.000127	CcSEcCtD
Duloxetine—Dermatitis—Etoposide—prostate cancer	5.57e-05	0.000126	CcSEcCtD
Duloxetine—Headache—Etoposide—prostate cancer	5.54e-05	0.000126	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—prostate cancer	5.54e-05	0.000126	CcSEcCtD
Duloxetine—Tension—Doxorubicin—prostate cancer	5.52e-05	0.000125	CcSEcCtD
Duloxetine—Decreased appetite—Prednisone—prostate cancer	5.51e-05	0.000125	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—prostate cancer	5.51e-05	0.000125	CcSEcCtD
Duloxetine—Malaise—Epirubicin—prostate cancer	5.48e-05	0.000124	CcSEcCtD
Duloxetine—Fatigue—Prednisone—prostate cancer	5.47e-05	0.000124	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—prostate cancer	5.46e-05	0.000124	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—prostate cancer	5.46e-05	0.000124	CcSEcCtD
Duloxetine—Syncope—Epirubicin—prostate cancer	5.45e-05	0.000124	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—prostate cancer	5.44e-05	0.000123	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—prostate cancer	5.44e-05	0.000123	CcSEcCtD
Duloxetine—Constipation—Prednisone—prostate cancer	5.42e-05	0.000123	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—prostate cancer	5.42e-05	0.000123	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—prostate cancer	5.41e-05	0.000123	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—prostate cancer	5.37e-05	0.000122	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—prostate cancer	5.34e-05	0.000121	CcSEcCtD
Duloxetine—Cough—Epirubicin—prostate cancer	5.3e-05	0.00012	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—prostate cancer	5.3e-05	0.00012	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—prostate cancer	5.28e-05	0.00012	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—prostate cancer	5.27e-05	0.000119	CcSEcCtD
Duloxetine—Nausea—Etoposide—prostate cancer	5.26e-05	0.000119	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—prostate cancer	5.25e-05	0.000119	CcSEcCtD
Duloxetine—Hypersensitivity—Capecitabine—prostate cancer	5.25e-05	0.000119	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisone—prostate cancer	5.23e-05	0.000119	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—prostate cancer	5.22e-05	0.000118	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—prostate cancer	5.2e-05	0.000118	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—prostate cancer	5.2e-05	0.000118	CcSEcCtD
Duloxetine—Gastrointestinal pain—Prednisone—prostate cancer	5.19e-05	0.000118	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—prostate cancer	5.17e-05	0.000117	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—prostate cancer	5.17e-05	0.000117	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—prostate cancer	5.17e-05	0.000117	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—prostate cancer	5.17e-05	0.000117	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—prostate cancer	5.16e-05	0.000117	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.14e-05	0.000117	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—prostate cancer	5.11e-05	0.000116	CcSEcCtD
Duloxetine—Asthenia—Capecitabine—prostate cancer	5.11e-05	0.000116	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—prostate cancer	5.07e-05	0.000115	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—prostate cancer	5.06e-05	0.000115	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—prostate cancer	5.05e-05	0.000115	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—prostate cancer	5.04e-05	0.000114	CcSEcCtD
Duloxetine—Urticaria—Prednisone—prostate cancer	5.04e-05	0.000114	CcSEcCtD
Duloxetine—Pruritus—Capecitabine—prostate cancer	5.04e-05	0.000114	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—prostate cancer	5.03e-05	0.000114	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—prostate cancer	5.03e-05	0.000114	CcSEcCtD
Duloxetine—Abdominal pain—Prednisone—prostate cancer	5.01e-05	0.000114	CcSEcCtD
Duloxetine—Body temperature increased—Prednisone—prostate cancer	5.01e-05	0.000114	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—prostate cancer	5e-05	0.000113	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—prostate cancer	4.97e-05	0.000113	CcSEcCtD
Duloxetine—Oedema—Epirubicin—prostate cancer	4.96e-05	0.000113	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—prostate cancer	4.96e-05	0.000113	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—prostate cancer	4.94e-05	0.000112	CcSEcCtD
Duloxetine—Infection—Epirubicin—prostate cancer	4.93e-05	0.000112	CcSEcCtD
Duloxetine—Cough—Doxorubicin—prostate cancer	4.91e-05	0.000111	CcSEcCtD
Duloxetine—Shock—Epirubicin—prostate cancer	4.88e-05	0.000111	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—prostate cancer	4.87e-05	0.000111	CcSEcCtD
Duloxetine—Diarrhoea—Capecitabine—prostate cancer	4.87e-05	0.000111	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—prostate cancer	4.86e-05	0.00011	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—prostate cancer	4.86e-05	0.00011	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—prostate cancer	4.86e-05	0.00011	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—prostate cancer	4.86e-05	0.00011	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—prostate cancer	4.84e-05	0.00011	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—prostate cancer	4.82e-05	0.000109	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—prostate cancer	4.8e-05	0.000109	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—prostate cancer	4.79e-05	0.000109	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—prostate cancer	4.79e-05	0.000109	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—prostate cancer	4.79e-05	0.000109	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—prostate cancer	4.77e-05	0.000108	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.76e-05	0.000108	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—prostate cancer	4.73e-05	0.000107	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—prostate cancer	4.73e-05	0.000107	CcSEcCtD
Duloxetine—Dizziness—Capecitabine—prostate cancer	4.71e-05	0.000107	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—prostate cancer	4.68e-05	0.000106	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—prostate cancer	4.68e-05	0.000106	CcSEcCtD
Duloxetine—Hypersensitivity—Prednisone—prostate cancer	4.67e-05	0.000106	CcSEcCtD
Duloxetine—Rash—Docetaxel—prostate cancer	4.64e-05	0.000105	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—prostate cancer	4.63e-05	0.000105	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—prostate cancer	4.63e-05	0.000105	CcSEcCtD
Duloxetine—Headache—Docetaxel—prostate cancer	4.61e-05	0.000105	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—prostate cancer	4.59e-05	0.000104	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—prostate cancer	4.59e-05	0.000104	CcSEcCtD
Duloxetine—Infection—Doxorubicin—prostate cancer	4.56e-05	0.000103	CcSEcCtD
Duloxetine—Asthenia—Prednisone—prostate cancer	4.55e-05	0.000103	CcSEcCtD
Duloxetine—Vomiting—Capecitabine—prostate cancer	4.53e-05	0.000103	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.52e-05	0.000103	CcSEcCtD
Duloxetine—Shock—Doxorubicin—prostate cancer	4.52e-05	0.000102	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—prostate cancer	4.5e-05	0.000102	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—prostate cancer	4.49e-05	0.000102	CcSEcCtD
Duloxetine—Rash—Capecitabine—prostate cancer	4.49e-05	0.000102	CcSEcCtD
Duloxetine—Pruritus—Prednisone—prostate cancer	4.49e-05	0.000102	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—prostate cancer	4.49e-05	0.000102	CcSEcCtD
Duloxetine—Dermatitis—Capecitabine—prostate cancer	4.49e-05	0.000102	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—prostate cancer	4.48e-05	0.000102	CcSEcCtD
Duloxetine—Headache—Capecitabine—prostate cancer	4.46e-05	0.000101	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—prostate cancer	4.46e-05	0.000101	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—prostate cancer	4.45e-05	0.000101	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—prostate cancer	4.44e-05	0.000101	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—prostate cancer	4.41e-05	0.0001	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—prostate cancer	4.38e-05	9.93e-05	CcSEcCtD
Duloxetine—Nausea—Docetaxel—prostate cancer	4.37e-05	9.91e-05	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—prostate cancer	4.37e-05	9.91e-05	CcSEcCtD
Duloxetine—Diarrhoea—Prednisone—prostate cancer	4.34e-05	9.84e-05	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—prostate cancer	4.31e-05	9.78e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—prostate cancer	4.28e-05	9.72e-05	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—prostate cancer	4.28e-05	9.7e-05	CcSEcCtD
Duloxetine—Constipation—Epirubicin—prostate cancer	4.24e-05	9.62e-05	CcSEcCtD
Duloxetine—Pain—Epirubicin—prostate cancer	4.24e-05	9.62e-05	CcSEcCtD
Duloxetine—Nausea—Capecitabine—prostate cancer	4.23e-05	9.59e-05	CcSEcCtD
Duloxetine—Dizziness—Prednisone—prostate cancer	4.19e-05	9.51e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.18e-05	9.49e-05	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—prostate cancer	4.15e-05	9.42e-05	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—prostate cancer	4.12e-05	9.35e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—prostate cancer	4.09e-05	9.27e-05	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—prostate cancer	4.08e-05	9.26e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—prostate cancer	4.06e-05	9.2e-05	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—prostate cancer	4.04e-05	9.17e-05	CcSEcCtD
Duloxetine—Vomiting—Prednisone—prostate cancer	4.03e-05	9.15e-05	CcSEcCtD
Duloxetine—Rash—Prednisone—prostate cancer	4e-05	9.07e-05	CcSEcCtD
Duloxetine—Dermatitis—Prednisone—prostate cancer	4e-05	9.06e-05	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—prostate cancer	3.99e-05	9.05e-05	CcSEcCtD
Duloxetine—Headache—Prednisone—prostate cancer	3.97e-05	9.01e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.96e-05	8.99e-05	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—prostate cancer	3.96e-05	8.98e-05	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—prostate cancer	3.94e-05	8.94e-05	CcSEcCtD
Duloxetine—Pain—Doxorubicin—prostate cancer	3.93e-05	8.9e-05	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—prostate cancer	3.93e-05	8.9e-05	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—prostate cancer	3.92e-05	8.9e-05	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—prostate cancer	3.92e-05	8.9e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—prostate cancer	3.78e-05	8.58e-05	CcSEcCtD
Duloxetine—Nausea—Prednisone—prostate cancer	3.77e-05	8.55e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—prostate cancer	3.75e-05	8.51e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—prostate cancer	3.65e-05	8.29e-05	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—prostate cancer	3.65e-05	8.27e-05	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—prostate cancer	3.63e-05	8.23e-05	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—prostate cancer	3.63e-05	8.23e-05	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—prostate cancer	3.56e-05	8.07e-05	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—prostate cancer	3.51e-05	7.96e-05	CcSEcCtD
Duloxetine—Diarrhoea—Epirubicin—prostate cancer	3.39e-05	7.7e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—prostate cancer	3.38e-05	7.67e-05	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—prostate cancer	3.29e-05	7.47e-05	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—prostate cancer	3.28e-05	7.44e-05	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—prostate cancer	3.25e-05	7.37e-05	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—prostate cancer	3.15e-05	7.16e-05	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—prostate cancer	3.14e-05	7.12e-05	CcSEcCtD
Duloxetine—Rash—Epirubicin—prostate cancer	3.13e-05	7.1e-05	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—prostate cancer	3.12e-05	7.09e-05	CcSEcCtD
Duloxetine—Headache—Epirubicin—prostate cancer	3.11e-05	7.05e-05	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—prostate cancer	3.04e-05	6.89e-05	CcSEcCtD
Duloxetine—Nausea—Epirubicin—prostate cancer	2.95e-05	6.68e-05	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—prostate cancer	2.92e-05	6.62e-05	CcSEcCtD
Duloxetine—Rash—Doxorubicin—prostate cancer	2.89e-05	6.57e-05	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—prostate cancer	2.89e-05	6.56e-05	CcSEcCtD
Duloxetine—Headache—Doxorubicin—prostate cancer	2.88e-05	6.52e-05	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—prostate cancer	2.73e-05	6.18e-05	CcSEcCtD
Duloxetine—CYP1A2—Metabolism—SULT2A1—prostate cancer	9.97e-06	5.25e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREBBP—prostate cancer	9.9e-06	5.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ITPR1—prostate cancer	9.85e-06	5.18e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1C3—prostate cancer	9.85e-06	5.18e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MED12—prostate cancer	9.81e-06	5.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—prostate cancer	9.81e-06	5.16e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PRKACB—prostate cancer	9.8e-06	5.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—prostate cancer	9.78e-06	5.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—prostate cancer	9.76e-06	5.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB3—prostate cancer	9.74e-06	5.13e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNG5—prostate cancer	9.73e-06	5.12e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—prostate cancer	9.73e-06	5.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGFR2—prostate cancer	9.73e-06	5.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP17A1—prostate cancer	9.69e-06	5.1e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAP2K1—prostate cancer	9.45e-06	4.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1R—prostate cancer	9.42e-06	4.96e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—prostate cancer	9.39e-06	4.94e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—prostate cancer	9.38e-06	4.94e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA3—prostate cancer	9.38e-06	4.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—prostate cancer	9.37e-06	4.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—prostate cancer	9.34e-06	4.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—JAK2—prostate cancer	9.33e-06	4.91e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—prostate cancer	9.3e-06	4.9e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—prostate cancer	9.29e-06	4.89e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOA2—prostate cancer	9.24e-06	4.86e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	9.21e-06	4.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—prostate cancer	9.19e-06	4.84e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—prostate cancer	9.03e-06	4.75e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGF2—prostate cancer	8.99e-06	4.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—prostate cancer	8.96e-06	4.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFRB—prostate cancer	8.95e-06	4.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HPGDS—prostate cancer	8.94e-06	4.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—prostate cancer	8.93e-06	4.7e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2C19—prostate cancer	8.89e-06	4.68e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—prostate cancer	8.87e-06	4.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—prostate cancer	8.86e-06	4.66e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—prostate cancer	8.81e-06	4.64e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ITGB3—prostate cancer	8.72e-06	4.59e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—prostate cancer	8.72e-06	4.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—prostate cancer	8.68e-06	4.57e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ACHE—prostate cancer	8.68e-06	4.57e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—prostate cancer	8.64e-06	4.55e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JAK2—prostate cancer	8.62e-06	4.54e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2E1—prostate cancer	8.61e-06	4.53e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2A6—prostate cancer	8.58e-06	4.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	8.54e-06	4.5e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—prostate cancer	8.54e-06	4.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—prostate cancer	8.52e-06	4.48e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NQO1—prostate cancer	8.51e-06	4.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB3—prostate cancer	8.46e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—prostate cancer	8.45e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR2—prostate cancer	8.45e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MDM2—prostate cancer	8.41e-06	4.43e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TH—prostate cancer	8.39e-06	4.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1C3—prostate cancer	8.34e-06	4.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—prostate cancer	8.32e-06	4.38e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP3A4—prostate cancer	8.3e-06	4.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PRKACB—prostate cancer	8.3e-06	4.37e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—prostate cancer	8.29e-06	4.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP17A1—prostate cancer	8.21e-06	4.32e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—prostate cancer	8.19e-06	4.31e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1B1—prostate cancer	8.16e-06	4.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—prostate cancer	8.14e-06	4.28e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BAD—prostate cancer	8.12e-06	4.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—prostate cancer	8.11e-06	4.27e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	8.1e-06	4.26e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GGT1—prostate cancer	7.9e-06	4.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—prostate cancer	7.87e-06	4.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—prostate cancer	7.87e-06	4.14e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—prostate cancer	7.87e-06	4.14e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA2—prostate cancer	7.83e-06	4.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOA1—prostate cancer	7.78e-06	4.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGF—prostate cancer	7.78e-06	4.09e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS1—prostate cancer	7.78e-06	4.09e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—prostate cancer	7.75e-06	4.08e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—prostate cancer	7.68e-06	4.04e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP19A1—prostate cancer	7.67e-06	4.04e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—prostate cancer	7.6e-06	4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—prostate cancer	7.57e-06	3.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GSK3B—prostate cancer	7.55e-06	3.97e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—prostate cancer	7.53e-06	3.96e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—prostate cancer	7.52e-06	3.96e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—prostate cancer	7.5e-06	3.95e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—prostate cancer	7.48e-06	3.94e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—prostate cancer	7.47e-06	3.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—prostate cancer	7.45e-06	3.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—prostate cancer	7.42e-06	3.9e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RXRA—prostate cancer	7.4e-06	3.9e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—prostate cancer	7.33e-06	3.86e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREBBP—prostate cancer	7.29e-06	3.84e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2E1—prostate cancer	7.29e-06	3.84e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—prostate cancer	7.26e-06	3.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—prostate cancer	7.23e-06	3.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NQO1—prostate cancer	7.21e-06	3.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—prostate cancer	7.2e-06	3.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—prostate cancer	7.17e-06	3.77e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—COMT—prostate cancer	7.13e-06	3.75e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—prostate cancer	7.12e-06	3.74e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TH—prostate cancer	7.11e-06	3.74e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—prostate cancer	7.1e-06	3.74e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—prostate cancer	7.09e-06	3.73e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—prostate cancer	7.07e-06	3.72e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.06e-06	3.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BAD—prostate cancer	7.05e-06	3.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP3A4—prostate cancer	7.03e-06	3.7e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7e-06	3.68e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ITPR1—prostate cancer	6.98e-06	3.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAP2K1—prostate cancer	6.96e-06	3.66e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—prostate cancer	6.92e-06	3.64e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1B1—prostate cancer	6.91e-06	3.64e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—prostate cancer	6.9e-06	3.63e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—prostate cancer	6.85e-06	3.61e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—prostate cancer	6.84e-06	3.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—prostate cancer	6.83e-06	3.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—prostate cancer	6.83e-06	3.6e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—prostate cancer	6.77e-06	3.56e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGF—prostate cancer	6.75e-06	3.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS1—prostate cancer	6.75e-06	3.55e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EP300—prostate cancer	6.75e-06	3.55e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GGT1—prostate cancer	6.69e-06	3.52e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF2—prostate cancer	6.62e-06	3.48e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—prostate cancer	6.6e-06	3.47e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA1—prostate cancer	6.59e-06	3.47e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—prostate cancer	6.56e-06	3.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GSK3B—prostate cancer	6.56e-06	3.45e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—prostate cancer	6.53e-06	3.44e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—prostate cancer	6.52e-06	3.43e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP19A1—prostate cancer	6.5e-06	3.42e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—prostate cancer	6.47e-06	3.4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—prostate cancer	6.4e-06	3.37e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—prostate cancer	6.39e-06	3.36e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAK2—prostate cancer	6.35e-06	3.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREBBP—prostate cancer	6.33e-06	3.33e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—prostate cancer	6.33e-06	3.33e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RXRA—prostate cancer	6.27e-06	3.3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—prostate cancer	6.26e-06	3.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—prostate cancer	6.22e-06	3.28e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—prostate cancer	6.22e-06	3.27e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MDM2—prostate cancer	6.2e-06	3.26e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—prostate cancer	6.18e-06	3.25e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ERCC2—prostate cancer	6.13e-06	3.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—prostate cancer	6.11e-06	3.21e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.1e-06	3.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	6.05e-06	3.18e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—COMT—prostate cancer	6.04e-06	3.18e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	6.03e-06	3.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—prostate cancer	6.01e-06	3.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	6.01e-06	3.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	5.95e-06	3.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	5.94e-06	3.13e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ITPR1—prostate cancer	5.92e-06	3.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—prostate cancer	5.88e-06	3.09e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—prostate cancer	5.88e-06	3.09e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—prostate cancer	5.86e-06	3.09e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.82e-06	3.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—prostate cancer	5.79e-06	3.05e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—prostate cancer	5.76e-06	3.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF2—prostate cancer	5.75e-06	3.03e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—prostate cancer	5.75e-06	3.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—prostate cancer	5.67e-06	2.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	5.66e-06	2.98e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARA—prostate cancer	5.66e-06	2.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	5.6e-06	2.95e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—prostate cancer	5.59e-06	2.94e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—prostate cancer	5.54e-06	2.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—prostate cancer	5.54e-06	2.91e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—prostate cancer	5.53e-06	2.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAK2—prostate cancer	5.51e-06	2.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—prostate cancer	5.51e-06	2.9e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—prostate cancer	5.43e-06	2.86e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—prostate cancer	5.42e-06	2.85e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	5.4e-06	2.84e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—prostate cancer	5.4e-06	2.84e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MDM2—prostate cancer	5.38e-06	2.83e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	5.34e-06	2.81e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—prostate cancer	5.32e-06	2.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—prostate cancer	5.3e-06	2.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—prostate cancer	5.24e-06	2.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—prostate cancer	5.24e-06	2.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	5.23e-06	2.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	5.22e-06	2.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—prostate cancer	5.21e-06	2.74e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ERCC2—prostate cancer	5.2e-06	2.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—prostate cancer	5.08e-06	2.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—prostate cancer	5.03e-06	2.65e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—prostate cancer	4.99e-06	2.63e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EP300—prostate cancer	4.97e-06	2.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	4.91e-06	2.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—prostate cancer	4.88e-06	2.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	4.86e-06	2.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.84e-06	2.55e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—prostate cancer	4.83e-06	2.54e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—prostate cancer	4.83e-06	2.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—prostate cancer	4.81e-06	2.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—prostate cancer	4.81e-06	2.53e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARA—prostate cancer	4.79e-06	2.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—prostate cancer	4.78e-06	2.52e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	4.7e-06	2.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—prostate cancer	4.69e-06	2.47e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—prostate cancer	4.66e-06	2.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	4.64e-06	2.44e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—prostate cancer	4.58e-06	2.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—prostate cancer	4.55e-06	2.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	4.53e-06	2.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—prostate cancer	4.52e-06	2.38e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—prostate cancer	4.5e-06	2.37e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CREBBP—prostate cancer	4.49e-06	2.36e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—prostate cancer	4.42e-06	2.33e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	4.41e-06	2.32e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—prostate cancer	4.33e-06	2.28e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	4.32e-06	2.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EP300—prostate cancer	4.31e-06	2.27e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.3e-06	2.26e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—prostate cancer	4.26e-06	2.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—prostate cancer	4.23e-06	2.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—prostate cancer	4.19e-06	2.21e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—prostate cancer	4.1e-06	2.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	4.09e-06	2.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—prostate cancer	4.08e-06	2.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—prostate cancer	4.05e-06	2.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—prostate cancer	4.02e-06	2.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—prostate cancer	4e-06	2.11e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—prostate cancer	3.88e-06	2.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CREBBP—prostate cancer	3.8e-06	2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—prostate cancer	3.76e-06	1.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	3.75e-06	1.97e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.71e-06	1.95e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—prostate cancer	3.68e-06	1.94e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—prostate cancer	3.68e-06	1.94e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	3.67e-06	1.93e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.61e-06	1.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—prostate cancer	3.56e-06	1.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—prostate cancer	3.47e-06	1.83e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—prostate cancer	3.41e-06	1.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—prostate cancer	3.25e-06	1.71e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—prostate cancer	3.21e-06	1.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	3.19e-06	1.68e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—prostate cancer	3.14e-06	1.65e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—prostate cancer	3.12e-06	1.64e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—prostate cancer	3.09e-06	1.62e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EP300—prostate cancer	3.06e-06	1.61e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—prostate cancer	3e-06	1.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—prostate cancer	2.83e-06	1.49e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—prostate cancer	2.72e-06	1.43e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—prostate cancer	2.61e-06	1.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EP300—prostate cancer	2.59e-06	1.36e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.26e-06	1.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.92e-06	1.01e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—prostate cancer	1.85e-06	9.73e-06	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—prostate cancer	1.57e-06	8.24e-06	CbGpPWpGaD
